BSE Sensex and Nifty pared gains in afternoon trade, with selling in banking and metal stocks offsetting gain in pharma and IT stocks.
An easing of global oil prices and gains in healthcare and IT stocks had helped Sensex, Nifty rebound nearly 0.6 per cent at day's high.
In oil, Brent crude was down 0.6 percent at $113.28 a barrel amid some easing of concerns of a supply disruption from the conflict in Iraq. Rupee was marginally higher at 60.12 per dollar vs yesterday's close of 60.14.
Among gainers, Ranbaxy Laboratories rose as much as 8 per cent after the US Food and Drug Administration said on Thursday it had approved the company's generic version of Novartis AG's blood pressure drug Diovan. Analysts say the current market size of Diovan in the United States is $1.7 billion and Ranbaxy can generate revenue of over $200 million from generic Diovan sales as it enjoys 180 days exclusivity for the same.
Also, Sun Pharmaceutical Industries, which in April agreed to buy Ranbaxy, rose 4 per cent to a year high of 674.95 on hopes that drugs such as Diovan would reduce its effective cost of acquiring Ranbaxy.
IT stocks were also in the limelight after Accenture reported a better-than-expected 7.5 per cent rise in quarterly net revenue. TCS rose nearly 4 per cent to a new year high of 2,398 while Infosys, Tech Mahindra and Wipro advanced between 1.5-3 per cent.
GAIL shares fell nearly 1.5 per cent following a blast at a gas pipeline of the state-owned energy company in Andhra Pradesh.
Selling pressure was seen in metal stocks with Hindalco down over 2 per cent and Sesa Sterlite losing 1 per cent. Banking stocks also fell with ICICI Bank fell 1.5 per cent while SBI and PNB fell 0.7 per cent.
At 12:38 p.m., the Sensex was up down 5 points at 25,057 while Nifty was slightly lower at 7,487.
An easing of global oil prices and gains in healthcare and IT stocks had helped Sensex, Nifty rebound nearly 0.6 per cent at day's high.
In oil, Brent crude was down 0.6 percent at $113.28 a barrel amid some easing of concerns of a supply disruption from the conflict in Iraq. Rupee was marginally higher at 60.12 per dollar vs yesterday's close of 60.14.
Among gainers, Ranbaxy Laboratories rose as much as 8 per cent after the US Food and Drug Administration said on Thursday it had approved the company's generic version of Novartis AG's blood pressure drug Diovan. Analysts say the current market size of Diovan in the United States is $1.7 billion and Ranbaxy can generate revenue of over $200 million from generic Diovan sales as it enjoys 180 days exclusivity for the same.
Also, Sun Pharmaceutical Industries, which in April agreed to buy Ranbaxy, rose 4 per cent to a year high of 674.95 on hopes that drugs such as Diovan would reduce its effective cost of acquiring Ranbaxy.
IT stocks were also in the limelight after Accenture reported a better-than-expected 7.5 per cent rise in quarterly net revenue. TCS rose nearly 4 per cent to a new year high of 2,398 while Infosys, Tech Mahindra and Wipro advanced between 1.5-3 per cent.
GAIL shares fell nearly 1.5 per cent following a blast at a gas pipeline of the state-owned energy company in Andhra Pradesh.
Selling pressure was seen in metal stocks with Hindalco down over 2 per cent and Sesa Sterlite losing 1 per cent. Banking stocks also fell with ICICI Bank fell 1.5 per cent while SBI and PNB fell 0.7 per cent.
At 12:38 p.m., the Sensex was up down 5 points at 25,057 while Nifty was slightly lower at 7,487.
No comments:
Post a Comment